nach oben

Erschienen in:

09.11.2016 | Herpesviren | Zertifizierte Fortbildung

Nervenschäden

Infektiologische Ursachen peripherer Neuropathien

verfasst von: Martin K. R. Svaèina, PD Dr. Helmar C. Lehmann

Erschienen in: NeuroTransmitter | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Infektionskrankheiten stellen in Europa, vor allem aber in den tropischen und subtropischen Klimazonen eine häufige Ursache für periphere Neuropathien dar. Durch eine weitere Zunahme der Mobilität, beispielsweise durch Fernreisen oder Wanderungsbewegungen, ist künftig mit einem weiteren Anstieg der Prävalenz infektiöser Polyneuropathien in Deutschland zu rechnen.

Neundörfer B HD. Polyneuropathien. Thieme. Stuttgart; 2006.

Robert Koch Institut: Schätzung der Prävalenz und Inzidenz von HIV-Infektionen in Deutschland 2014, Epid Bull 45/2015.

Hahné SJM, Veldhuijzen IK, Wiessing L, Lim T-A, Salminen M, Laar M van de. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13(1):181. doi:10.1186/1471-2334-13-181.CrossRefPubMedPubMedCentral

Deutscher Reiseverband. Zahlen Zum Deutschen Reisemarkt.; 2014.

Khattab MA, Eslam M, Alavian SM. Hepatitis c virus as a multifaceted disease: A simple and updated approach for extrahepatic manifestations of hepatitis c virus infection. Hepat Mon. 2010;10(4):258–269.PubMedPubMedCentral

Nemni R, Sanvito L, Quattrini a, Santuccio G, Camerlingo M, Canal N. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry. 2003;74(9):1267–1271. doi:10.1136/jnnp.74.9.1267.CrossRefPubMedPubMedCentral

Téllez-Zenteno JF, Calva-Mercado J, Weder-Cisneros N, Estañol B, Montes J, Rosales M, Plascencia N, Domínguez JC, Soto-Ramirez L, Ortiz-Nieva G, García-Ramos G. Prevalence and risk factors associated with the presence of peripheral neuropathy in patients with hepatitis C virus infection. J Clin Neuromuscul Dis. 2003 Mar;4(3):109–14.CrossRefPubMed

Chin RL, Sander HW, Brannagan 3rd TH, De Sousa E, Latov N. Demyelinating neuropathy in patients with hepatitis C virus infection. J Clin Neuromuscul Dis. 2010;11(4):209–212. doi:{rs 10.1097/CND.0b013e3181b701c1 DOI}.CrossRefPubMed

Yoon MS, Obermann M, Dockweiler C, et al. Sensory neuropathy in patients with cryoglobulin negative hepatitis-C infection. J Neurol. 2011;258(1):80–88. doi:10.1007/s00415-010-5686-1.CrossRefPubMed

10.

Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887. doi:10.1056/NEJMoa1214853.CrossRefPubMed

11.

Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221. doi:10.1056/NEJMoa1306218.CrossRefPubMed

12.

Hahn K, Maschke M, Eggers C, Husstedt IW, Arendt G. [Update HIV and neurology]. Dtsch Med Wochenschr. 2016;141(1):51–57. doi:10.1055/s-0041-102893.PubMed

13.

Power C, Boissé L, Rourke S, Gill MJ. NeuroAIDS: an evolving epidemic. Can J Neurol Sci. 2009;36:285–295.CrossRefPubMed

14.

Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology. 2002;58(1):115–119. doi:10.1212/WNL.58.1.115.CrossRefPubMed

15.

Conti L, Fantuzzi L, Del Cornò M, Belardelli F, Gessani S. Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: Implications for AIDS pathogenesis. Immunobiology. 2004;209(1-2):99–115. doi:10.1016/j.imbio.2004.02.008.CrossRefPubMed

16.

Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol. 2006;1(2):138–151. doi:10.1007/s11481-006-9011-9.CrossRefPubMed

17.

Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci. 2001;21(14):5027–5035. doi:21/14/5027 [pii].PubMed

18.

Chen X, Levine JD. Mechanically-evoked C-fiber activity in painful alcohol and AIDS therapy neuropathy in the rat. Mol Pain. 2007;3:5. doi:10.1186/1744-8069-3-5.CrossRefPubMedPubMedCentral

19.

Arendt G, Nolting T. [Neuro-AIDS in the cART era]. Fortschr Neurol Psychiatr. 2012;80(8):450–457. doi:10.1055/s-0032-1313191.CrossRefPubMed

20.

Anderson TD, Davidovich A, Arceo R, Brosnan C, Arezzo J, Schaumburg H. Peripheral neuropathy induced by 2‵,3‵-dideoxycytidine. A rabbit model of 2‵,3‵-dideoxycytidine neurotoxicity. Lab Invest. 1992;66(1):63–74.PubMed

21.

Feldman D, Anderson TD. Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2‵3‵-dideoxycytidine. Acta Neuropathol. 1994;87(1):71–80. doi:10.1007/BF00386256.CrossRefPubMed

22.

Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3‵-dideoxycytidine (ddC). Lab Invest. 2001;81(11):1537–1544. doi:10.1038/labinvest.3780367.CrossRefPubMed

23.

Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22(6):685–708. doi:10.1016/S0149-2918(00)90004-3.CrossRefPubMed

24.

Joseph EK, Chen X, Khasar SG LJ (2004). N, AIDS mechanism of enhanced nociception in a model of, Pain therapy-induced painful peripheral neuropathy in the rat., 107:147–158. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 107147–158.

25.

Bhangoo SK, Petty L, White FA. Animal models of HIV-associated painful sensory neuropathy. Neuromethods. 2011;49:171–179. doi:10.1007/978-1-60761-880-5_10.CrossRef

26.

Zheng X, Ouyang H, Liu S, Mata M, Fink DJ, Hao S. TNF?? is involved in neuropathic pain induced by nucleoside reverse transcriptase inhibitor in rats. Brain Behav Immun. 2011;25(8):1668–1676. doi:10.1016/j.bbi.2011.06.010.CrossRefPubMedPubMedCentral

27.

Wallace VCJ, Blackbeard J, Segerdahl AR, et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain. 2007;130(Pt 10):2688–2702. doi:10.1093/brain/awm195.CrossRefPubMedPubMedCentral

28.

Joseph EK, Levine JD. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci. 2004;20(11):2896–2902. doi:10.1111/j.1460-9568.2004.03750.x.CrossRefPubMed

29.

Keswani SC, Jack C, Zhou C HA. Establishment of a rodent model of HIV-associated sensory neuropathy.No Title. J Neurosci 2610299–10304. 2006.

30.

Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6(11):1015–1028. doi:10.1016/S1474-4422(07)70267-3.CrossRefPubMed

31.

Steiner I. Herpes virus infection of the peripheral nervous system. In: Handbook of Clinical Neurology, Vol.115. Elsevier Ltd; 2013:543-558.

32.

Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186 Suppl:S3-S28. doi:10.1086/343739.

33.

Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–973. doi:10.1001/jama.296.8.964.CrossRefPubMed

34.

Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: Identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996};124(1 I):27–30. doi:7503474.CrossRefPubMed

35.

Wagstaff AJ, Faulds D, Goa KL. Aciclovir. Drugs. 2012;47(1):153–205. doi:10.2165/00003495-199447010-00009.CrossRef

36.

Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361–381. doi:10.1074/jbc.M110.210575.PubMedPubMedCentral

37.

Kang JH, Sheu JJ, Lin HC. Increased Risk of Guillain-Barre Syndrome following Recent Herpes Zoster: A Population-Based Study across Taiwan. Clin Infect Dis. 2010;51(5):525–530. doi:Doi 10.1086/655136.CrossRefPubMed

38.

Kost RG, Straus SE. Postherpetic neuralgia—pathogenesis, treatment, and prevention. N Engl J Med. 1996;335(1):32–42. doi:10.1056/NEJM199607043350107.CrossRefPubMed

39.

Ifuku M, Iseki M, Hidaka I, Morita Y, Komatus S, Inada E. Replacement of Gabapentin with Pregabalin in Postherpetic Neuralgia Therapy. Pain Med. 2011;12(7):1112–1116. doi:10.1111/j.1526-4637.2011.01162.x.CrossRefPubMed

40.

Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV. In: Journal of Medical Virology. Vol 70.; 2003. doi:10.1002/jmv.10317.

41.

Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014 Oct 16;371 (16):1526–33. doi: 10.1056/NEJMcp1403062.

42.

Cannon MJ. Congenital cytomegalovirus (CMV) epidemiology and awareness. J Clin Virol. 2009;46(SUPPL. 4). doi:10.1016/j.jcv.2009.09.002.

43.

Kotton CN. CMV: Prevention, Diagnosis and Therapy. Am J Transplant. 2013;13 Suppl 3:24–40; quiz 40. doi:10.1111/ajt.12006.CrossRefPubMed

44.

Caudie C, Pinon AQ, Taravel D, et al. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barr?? syndrome patients. J Neurol. 2011;258(11):1958–1964. doi:10.1007/s00415-011-6042-9.CrossRefPubMed

45.

Tarulli AW, Raynor EM. Lumbosacral Radiculopathy. Neurol Clin. 2007;25(2):387–405. doi:10.1016/j.ncl.2007.01.008.CrossRefPubMed

46.

Stanojevic M, Zerjav S, Jevtovic D, Salemovic D, Ranin J. CMV DNA in blood and CSF of HIV infected patients. Virus Res. 2002;85(1):117–122. doi:10.1016/S0168-1702(02)00023-0.CrossRefPubMed

47.

Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology. 1996;47(5):1254–1259. http://www.ncbi.nlm.nih.gov/pubmed/8909439.CrossRefPubMed

48.

Halperin JJ, Little BW, Coyle PK, Dattwyler RJ. Lyme disease: cause of a treatable peripheral neuropathy. Neurology. 1987;37(11):1700–1706. doi:10.1212/WNL.37.11.1700.CrossRefPubMed

49.

Monteyne P, Dupuis MJ, Sindic CJ. [Neuritis of the serratus anterior muscle associated with Borrelia burgdorferi infection]. Rev Neurol. 1994;150(1):75–77. http://www.ncbi.nlm.nih.gov/pubmed/7801047.PubMed

50.

Muley SA PG. Antibiotic responsive demyelinating neuropathy related to lyme disease. Neurol 2009; 721786–1787.

51.

Diagnostik Und Therapie Der Lyme-Borreliose. Leitlinien Der Deutschen Borreliose-Gesellschaft.; 2011.

52.

World Health Organization. Global Leprosy Situation, 2006. Wkly Epidemiol Rec. 2010;(32):309-316. doi:02/10/2012.

53.

Sindic CJ. Infectious Neuropathies. Curr Opin Neurol 2013, 26510–515.

54.

Britton WJ, Lockwood DNJ. Leprosy. In: Lancet. Vol 363.; 2004:1209-1219. doi:10.1016/S0140-6736(04)15952-7.

55.

Antunes SLG, Chimelli L, Jardim MR et al. Histopathological examination of nerve samples from pure neural leprosy patients: obtaining maximum information to improve diagnostic efficiency. Mem Inst Oswaldo Cruz 2012; 107 246–253.CrossRefPubMed

56.

Jardim MR, Illarramendi X, Nascimento OJ et al. Pure neural leprosy: steroids prevent neuropathy progression. Arq Neuropsiquiatr 2007; 65969–973

57.

Dammacco, F und Sansonno, D. Therapy for Hepatitis C Virus-Related Cryoglobulinemic Vasculitis. N Engl J Med 2013; 369:1035–1045CrossRefPubMed

Titel: Nervenschäden
Infektiologische Ursachen peripherer Neuropathien
verfasst von: Martin K. R. Svaèina
PD Dr. Helmar C. Lehmann
Publikationsdatum: 09.11.2016
Verlag: Springer Medizin
Schlagwörter: Herpesviren
HIV
Neuro-Borreliose
Schädigung einzelner Nerven
Polyneuropathie
Hepatitis C
Herpes simplex Typ 1
Herpes simplex Typ 2
Varizella-Zoster-Virus
Cytomegalievirus
Herpes zoster
Erschienen in: NeuroTransmitter / Ausgabe 11/2016
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI: https://doi.org/10.1007/s15016-016-5402-1

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Förderung für europäisch-indischen Forschungsverbund

Eine große Arbeit — aber keine leichte Kost

M. Parkinson — neuer COMT-Hemmer wirkt kontinuierlich über 24 Stunden

Kein Zusatznutzen bei Epilepsie zugestanden

Im Schlaf beschimpft und würgt er seine Freundin

Der neue Begriff der Pflegebedürftigkeit aus Sicht der Pflegewissenschaft